To confirm the hypothesis that targeting GLI1 is of critical therapeutic value in T-cell lymphomas, lentivirus-mediated RNA interference was carried out to specifically knockdown GLI1 expression in the three cell lines (Jurkat, Karpass299 and Myla3676 cells). Here, GLI1 is linked to T-cell non-Hodgkin lymphoma.